Cargando…

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors

This phase I, dose-escalation trial evaluates the safety of combining interferon-gamma (IFN-γ) and nivolumab in patients with metastatic solid tumors. Twenty-six patients are treated in four cohorts assessing increasing doses of IFN-γ with nivolumab to evaluate the primary endpoint of safety and det...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zibelman, Matthew, MacFarlane, Alexander W., Costello, Kimberly, McGowan, Thomas, O’Neill, John, Kokate, Rutika, Borghaei, Hossein, Denlinger, Crystal S., Dotan, Efrat, Geynisman, Daniel M., Jain, Angela, Martin, Lainie, Obeid, Elias, Devarajan, Karthik, Ruth, Karen, Alpaugh, R. Katherine, Dulaimi, Essel Al-Saleem, Cukierman, Edna, Einarson, Margret, Campbell, Kerry S., Plimack, Elizabeth R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374608/ https://www.ncbi.nlm.nih.gov/pubmed/37500647 http://dx.doi.org/10.1038/s41467-023-40028-z

Ejemplares similares

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
por: Ghatalia, Pooja, et al.
Publicado: (2018)

Matrix-regulated integrin α(v)β(5) maintains α(5)β(1)-dependent desmoplastic traits prognostic of neoplastic recurrence
por: Franco-Barraza, Janusz, et al.
Publicado: (2017)

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
por: Jang, H. Josh, et al.
Publicado: (2023)

Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature
por: Barth, Peter, et al.
Publicado: (2015)

Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma
por: Ghatalia, Pooja, et al.
Publicado: (2019)

Correction to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma
por: Ghatalia, Pooja, et al.
Publicado: (2019)

Role of immunotherapy in localized muscle invasive urothelial cancer
por: Kaur, Jasmeet, et al.
Publicado: (2021)

The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013–2016 from the ClinicalTrials.gov Website
por: Ghatalia, Pooja, et al.
Publicado: (2017)

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
por: Bilusic, Marijo, et al.
Publicado: (2022)

Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing
por: Fernandez, Sandra V., et al.
Publicado: (2023)

Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC
por: Ibragimova, Ilsiya, et al.
Publicado: (2013)

Impact of Clinical Markers of Nutritional Status and Feeding Jejunostomy Use on Outcomes in Esophageal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
por: Jain, Rishi, et al.
Publicado: (2020)

Case report: reinitiating pembrolizumab treatment after small bowel perforation
por: Beck, Tim N., et al.
Publicado: (2019)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
por: Zhigarev, Dmitry, et al.
Publicado: (2022)

Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
por: Vijayvergia, Namrata, et al.
Publicado: (2020)

Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma
por: Jiang, Wei, et al.
Publicado: (2017)

Genomic imbalances in peripheral blood confirm the diagnosis of myelodysplastic syndrome in a patient presenting with non-immune hemolytic anemia
por: Zahid, Mohammad Faizan, et al.
Publicado: (2016)

Long-Lived Bright Red Emitting Azaoxa-Triangulenium Fluorophores
por: Maliwal, Badri P., et al.
Publicado: (2013)

Expression of Thymidine Phosphorylase in Lymph Nodes Involved with Mycosis Fungoides and Sézary Syndrome
por: Nie, Xingcao, et al.
Publicado: (2011)

Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma
por: Jiang, Wei, et al.
Publicado: (2016)

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
por: Liu, David, et al.
Publicado: (2017)

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
por: Atkins, Michael B., et al.
Publicado: (2022)

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
por: Pazina, Tatiana, et al.
Publicado: (2021)

A global profile of gene promoter methylation in treatment-naïve urothelial cancer
por: Ibragimova, Ilsiya, et al.
Publicado: (2014)

Light chain cast nephropathy caused by plasmablastic lymphoma of the bladder
por: Jafarizade, Mehrian, et al.
Publicado: (2021)

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
por: Atkins, Michael B, et al.
Publicado: (2023)

Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
por: Winer, Arthur, et al.
Publicado: (2021)

Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review
por: Ioffe, Dina, et al.
Publicado: (2021)

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
por: Horisberger, Alice, et al.
Publicado: (2018)

Elevated Expression of Stromal Palladin Predicts Poor Clinical Outcome in Renal Cell Carcinoma
por: Gupta, Vivekanand, et al.
Publicado: (2011)

Human factors and pathways essential for mediating epigenetic gene silencing
por: Poleshko, Andrey, et al.
Publicado: (2014)

Genome-Wide Promoter Methylome of Small Renal Masses
por: Ibragimova, Ilsiya, et al.
Publicado: (2013)

S100B Up-Regulates Macrophage Production of IL1β and CCL22 and Influences Severity of Retinal Inflammation
por: Niven, Jennifer, et al.
Publicado: (2015)

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
por: Zhang, Tian, et al.
Publicado: (2020)

Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors
por: McGillivray, Erin, et al.
Publicado: (2023)

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Sznol, Mario, et al.
Publicado: (2015)

Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer
por: Arisi, Maria F., et al.
Publicado: (2022)

Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma
por: Geynisman, Daniel M., et al.
Publicado: (2015)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bfkb92np7q9gjt6umq2egsi8ke